For years, American Wegovy patients have been using a remarkably inflexible delivery system for a disease that is anything but predictable. One dose comes in one pen, you inject it once, and then the entire device goes into the trash. If your prescribed dose is 2.4 mg, that pen delivers 2.4 mg. There has been very little flexibility built into the hardware itself.
That may be about to change. On The Pen has now verified with multiple credible sources that Novo Nordisk is preparing to launch the Wegovy FlexTouch pen for the 2.4 mg dose in the United States in the coming weeks.
A few months ago, we noted that the moves were being made with the FDA that could potentially set the stage for this launch. Novo Nordisk has now secured that approval for a U.S. Wegovy FlexTouch presentation containing 9.6 mg of semaglutide in 3 mL, with a single pen intended to deliver four labeled doses of 2.4 mg. The question is when patients will actually begin seeing it at pharmacies, and my sources tell me that answer is soon.
What exactly is changing?
Most Americans currently know injectable Wegovy as a box containing four disposable pens. Each pen is used for one injection and then discarded. The new FlexTouch presentation fundamentally changes that experience because one pen contains four weekly 2.4 mg doses, with disposable needles changed between injections.
If the device sounds familiar, there is a reason. FlexTouch is the same general multi-dose pen platform Americans have already seen used with Novo Nordisk products such as Ozempic. Instead of opening a new complete injection device every week, patients keep the same pen and attach a new needle for each dose.
From a convenience and waste standpoint alone, that is a meaningful change. Instead of four complete pens filling a refrigerator and eventually a trash can, a patient would use one pen over approximately four weeks.
But I also know exactly where the conversation around this is going to go, because patients are going to look at this device and immediately ask whether it means Wegovy dosing is about to become more flexible.
Why only the 2.4 mg dose?
Sources familiar with the upcoming rollout tell On The Pen that this launch will apply specifically to the 2.4 mg Wegovy dose. At least initially, the lower Wegovy strengths are not expected to be part of the FlexTouch launch in the United States.
That actually makes commercial sense. The 2.4 mg dose has historically been the primary maintenance dose for Wegovy, meaning patients who successfully titrate to it may remain there for a prolonged period of time. A four-dose reusable pen format is particularly well suited to that phase of treatment.
The FDA labeling supports exactly that configuration. The FlexTouch presentation contains 9.6 mg of semaglutide in 3 mL and is designed around four weekly 2.4 mg doses, while the familiar single-dose Wegovy presentations remain part of the product lineup.
In other words, this does not appear to be an immediate wholesale replacement of every Wegovy pen currently sold in America. It looks much more like Novo is starting with the maintenance dose, via the cash pay channel, which is the most logical place to begin for a number of reasons.
Then there is the money
This is where the story could become much more interesting. Novo Nordisk has been increasingly aggressive with direct-to-patient and self-pay pricing as the competition for obesity patients has intensified, and the introduction of a four-dose FlexTouch pen adds another variable to that strategy.
The most obvious patient question will be whether the FlexTouch presentation is priced and discounted exactly like the existing box. Theoretically, a physician may elect to prescribe the higher dose flexible pen, and give patients using lower doses a pathway to refill their medication less often. Of course this would go against the label and package insert, but we all know it will happen.
The coolest part? Novo doesn’t have a 45 day refill requirement like Eli Lilly does.
Cheers,
DK
